An update from Mainz Biomed B.V. ( (MYNZ) ) is now available.
On March 13, 2025, Mainz Biomed announced a groundbreaking discovery in collaboration with Liquid Biosciences, revealing mRNA biomarkers for blood-based detection of pancreatic cancer. The discovery demonstrated a sensitivity of 95% and specificity of 98%, potentially positioning the test as the most accurate on the market. Mainz Biomed has entered an exclusive licensing agreement with Liquid Biosciences to develop this test further, with plans for FDA applications. This development marks a significant milestone in the company’s efforts to enhance early cancer detection and could significantly impact its market positioning and stakeholder interests.
More about Mainz Biomed B.V.
Mainz Biomed N.V. is a molecular genetics diagnostic company that specializes in the early detection of cancer. The company’s flagship product is ColoAlert®, a non-invasive early-detection test for colorectal cancer, marketed across Europe. Mainz Biomed is also developing PancAlert, an early-stage pancreatic cancer screening test.
YTD Price Performance: 13.72%
Average Trading Volume: 214,985
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $10.35M
Learn more about MYNZ stock on TipRanks’ Stock Analysis page.